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Intensive care unit patients often have complex disorders. For
instance, bouts of inflammation, trauma and
ischaemia/reperfusion may occur sequentially or
synchronously in patients following surgery, sepsis or shock,
thereby upregulating inflammatory and metabolic responses,
including cytokine release, protein breakdown and insulin
resistance [1–4]. In spite of elevated insulin levels, insulin
resistance at the receptor and postreceptor levels may
contribute to hyperglycaemia, even in non-diabetic persons,
particularly when stress hormones that promote
glycogenolysis are released, including catecholamines and
cortisol [2,3,5]. ‘Stress’ hyperglycaemia can be reproduced
after administration of minute amounts of endotoxin to healthy
volunteers or by injecting several stress hormones at the
same time [5]. Stress hyperglycaemia may occur during the
acute phase of illness in 5–30% of patients with stroke,
myocardial infarction, sepsis, burns, trauma, surgery and
other conditions.
Hyperglycaemia
Recent evidence suggests that even mild hyperglycaemia is
harmful in animals and humans, and aggravates
ischaemia/reperfusion damage to heart and brain. Myocardial
infact size in humans, with or without diabetes, is greater in
the presence of hyperglycaemia [6]. That the former results
from the latter (i.e. more severe stress hyperglycaemia
causes greater infarct size) rather than vice versa is
supported by animal studies [7]. Similarly, hyperglycaemia is
associated with poor neurological outcome after traumatic
brain injury and stroke [8]. In rodents hyperglycaemia
aggravates endotoxin shock, and insulin treatment may
decrease mortality [9,10]. Hyperglycaemia may contribute to
morbidity and mortality after burns or surgery in humans
[3,11]. Therefore, during the course of diabetes mellitus but
also during the course of stress hyperglycaemia, untreated or
insufficiently controlled hyperglycaemia may adversely impact
on organ function after inflammation, trauma or
ischaemia/reperfusion, and consequently may have a
detrimental impact on morbidity and mortality.
Apart from the detrimental effect of even mild hyperglycaemia
on bacterial defences, and wound healing and repair after
ischaemia/reperfusion [11], there are various other potential
mechanisms to explain the harmful effect of hyperglycaemia.
They include the effect of hyperglycaemia on metabolic
mitochondrial pathways, which results in oxidative stress and
increased superoxide production [12]. Cytosolic oxygen
radical production as a result of hyperglycaemia may arise
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Abstract
Stress hyperglycaemia is a common event in acute critical illness. There is increasing evidence that
maintaining normoglycaemia and treatment with insulin (or with glucose–insulin–potassium [GIK]),
even in non-diabetic persons, is helpful in limiting organ damage after myocardial infarction, stroke,
traumatic brain injury and other conditions, even though the conditions may be accompanied by insulin
resistance. A landmark study now suggests that maintaining normoglycaemia with intensive insulin
treatment in a heterogeneous population of critically ill patients decreases morbidity and mortality. The
potential mechanisms that underlie such a beneficial effect are discussed.
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from non-enzymatic glycation, auto-oxidation of glucose and
the polyol pathway [13]. Hyperglycaemia-induced oxygen
radicals may scavenge endogenous nitric oxide, thereby
increasing electrical instability of the heart and peripheral
vascular tone [14]. Also, in humans acute hyperglycaemia
attenuates endothelial nitric oxide-dependent dilatation of the
brachial artery [13]. Hyperglycaemia may increase neutrophil
activation and interaction with endothelium following
ischaemia/reperfusion [15]. Diabetes/hyperglycaemia may
attenuate ischaemic preconditioning of the heart, possibly by
inhibiting activation of ATP-sensitive potassium channels that
may afford protection by activating glycolysis in the cytosol
[7,16]. This may also explain why ATP-sensitive potassium
channel blockers (e.g. sulfonylurea drugs) may abolish,
whereas insulin may not abolish and may even enhance
protection afforded by ischaemic preconditioning of the human
myocardium [7]. Finally, hyperglycaemia enhances proteolysis
in healthy volunteers, even during hyperinsulinaemia.
Insulin treatment
For decades it has been advocated that fasting diabetic
persons be treated with a combined glucose and insulin
infusion before invasive procedures or surgery [17]. The
basis for this recommendation was improved diabetic control
and thereby fewer wound infections and better wound
healing. However, we now know that this view may be too
simplistic. The effects of GIK infusion may extend beyond
control of hyperglycaemia alone [4]. Indeed, the use of GIK in
patients with myocardial infarction and shock was originally
studied decades ago, but has recently undergone a revival. In
both diabetic and non-diabetic patients with myocardial
infarction, GIK infusion may salvage myocardium, improve
heart function without an increase in myocardial oxygen
demand, and decrease mortality by an absolute 10%,
particularly in those receiving prior reperfusion therapy,
provided that hyperglycaemia is prevented. This was
demonstrated in a recent landmark trial [18,19]. Animal
studies [20] suggest that this effect may partly be
independent of glucose. Also, bolus infusion of hyperosmolar
GIK improved cardiac output and heart function in canine
endotoxin and human septic shock, but this may relate to the
positive inotropic effect of hyperosmolarity or insulin rather
than to a metabolic effect, in spite of myocardial insulin
resistance [21,22]. In diabetic and non-diabetic persons, GIK
infusion after cardiac surgery may improve heart function and
expedite recovery [23]. Treatment with GIK may also improve
outcome in stroke patients [24].
Those studies have now been supplemented by a large trial
conducted in a heterogeneous group of 1548 critically ill
patients [25]. That trial demonstrated that intensive insulin
treatment to avoid hyperglycaemia in diabetic and non-
diabetic persons is associated with a decrease in mortality,
from 8% in the less intensively treated (blood glucose
maintained between 10.0 and 11.1 mmol/l) to 4.6% in the
intensively treated patients (blood glucose maintained below
6.1 mmol/l). The reduction in mortality was even greater in
sicker patients with a duration of stay longer than 5 days. In
that single-centre, landmark trial, patients with sepsis
appeared to benefit the most. The effect of insulin apparently
occurred even in the assumed presence of insulin resistance.
Hypoglycaemia occurred somewhat more frequently in the
intensive insulin group, but appeared well controlled and
relatively harmless. What could underlie these beneficial
effects and what are the potential mechanisms involved?
Mechanisms of the action of insulin
The basis of the beneficial effect of insulin treatment, despite
potential insulin resistance in conditions associated with
trauma, inflammation and ischaemia/reperfusion, may be
multifactorial. On the one hand correction of hyperglycaemia
may prevent its adverse effects. On the other hand insulin,
whether or not combined with glucose to compensate for
increased skeletal muscle glucose uptake, and even in the
critically ill with insulin resistance [2], may also benefit non-
diabetic or normoglycaemic patients (Table 1).
Glucose or insulin started preoperatively may decrease
postoperative insulin resistance [3]. Bolus infusion of insulin
combined with glucose may have vasodilatory properties,
may inhibit fatty acid, and may increase glucose uptake in
ischaemic tissues for anaerobic ATP production following
augmented glycolysis. Thus, insulin may limit the fall in tissue
high-energy phosphates that may occur during ischaemia,
despite its potential to increase lactate concentrations.
Insulin may also stimulate pyruvate dehydrogenase during
ischaemia, and thereby exerts a beneficial effect associated
with an improved energy state and less lactate production, at
least in cultures of cardiomyocytes taken from patients during
cardiac surgery [26]. Similarly, pyruvate infusions and
enhanced uptake thereof in the tricarboxylic acid cycle may
decrease the cytosolic redox state and oxygen radical
production, maintain phosphorylation potential and thus limit
energy depletion during ischaemia [27]. Insulin may have
anti-inflammatory properties by inhibiting production of
tumour necrosis factor-α, superoxide radicals and
intercellular adhesion molecule-1 in macrophages,
leucocytes and endothelium; it may inhibit harmful
macrophage-inhibitory factor; and it may potentiate release of
endothelial nitric oxide synthase and endothelin [4].
Insulin may increase levels of insulin-like growth factor (IGF)-I,
a mediator of growth hormone action, and may suppress
hepatic synthesis of IGF-1-binding protein, which binds and
limits free circulating IGF-I; thus, during critical illness
circulating levels of IGF-I are low and those of IGF-1-binding
protein are high [28,29]. Insulin may therefore increase the
bioavailability of IGF-I [28].
IGF-I may mimick some of the actions of insulin and may have
various beneficial actions, but the anabolic properties may
not exceed those of insulin, at least in endotoxaemic ratsCritical Care    April 2002 Vol 6 No 2 Groeneveld et al.
[10]. Otherwise, muscle protein synthesis would also
become relatively resistant to insulin during sepsis [30].
There have been some small trials on the value of IGF-I
administration in the critically ill, but results have been
disappointing thus far. Insulin may have anabolic properties in
the critically ill, burned and catabolic patient [31]. It
stimulates protein synthesis in skeletal muscle [31]. Both
IGF-I and insulin may inhibit postischaemic apoptosis,
energetic failure and damage of cardiac tissue, both in vitro
and in animals [20,26]. Insulin may also potentiate ischaemic
preconditioning, as described above.
Therefore, there are multiple pathways through which insulin
treatment may decrease morbidity and mortality in a variety of
critical conditions. Some caution is warranted, however,
because hyperinsulinaemia per se may have some adverse
effects, including endothelial oxygen radical production [13,32].
Conclusion
The finding of the beneficial effect of intensive insulin therapy
in critically ill patients to maintain blood glucose levels below
6.1 mmol/l, as reported by Van den Berghe et al. [25], has a
relatively firm albeit multifactorial basis. Those findings should
prompt intensivists to institute strict (perhaps stricter than is
commonly advocated [17]) control of blood glucose, with the
help of the ‘wonder drug’ insulin. However, a survival benefit
has also recently been shown for administration of
hydrocortisone [33]. Hydrocortisone infusion may increase
blood glucose levels and thereby necessitate concomitant
infusion of insulin. Hence, the interaction between these
hormones may be a subject for further therapeutic study.
Nevertheless, the study reported by Van den Berghe et al.
[25] is certainly a major step forward in the treatment of
critically ill patients, particularly in the context of failure of most
large trials on the value of immunomodulatory treatment of
sepsis and shock to show a beneficial impact. Clearly, a
limitation of intensive insulin treatment in critically ill patients
on sedation is the potential occurrence of hidden
hypoglycaemia [31]. Hence, intensive insulin treatment
warrants intensive monitoring of blood glucose concentration.
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